{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:46:13Z","timestamp":1795052773020,"version":"4.10.2"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.atherosclerosis.2026.120755","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T10:19:11Z","timestamp":1779617951000},"page":"120755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Remnant cholesterol \u2014 The transition from biomarker to risk factor"],"prefix":"10.1016","volume":"417","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7741-4102","authenticated-orcid":false,"given":"Deepthi Nishi","family":"Velamuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4711-5492","authenticated-orcid":false,"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-8818","authenticated-orcid":false,"given":"Sascha N.","family":"Goonewardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120755_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120529","article-title":"Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: what we know and what we need to know","volume":"410","author":"Chapman","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","volume":"28","author":"Varbo","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","article-title":"Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using Non-HDL cholesterol","volume":"84","author":"Bjornson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cgh.2020.08.016","article-title":"Genetic variants associated with increased plasma levels of triglycerides, via effects on the lipoprotein lipase pathway, increase risk of acute pancreatitis","volume":"19","author":"Hansen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117556","article-title":"Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial","volume":"393","author":"Doi","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0022-2275(20)41594-9","article-title":"Fractionation of human serum lipoproteins by single-spin gradient ultracentrifugation: quantification of apolipoproteins B and A-1 and lipid components","volume":"18","author":"Foreman","year":"1977","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib13","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstrom","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib14","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/clinchem\/37.3.377","article-title":"Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy","volume":"37","author":"Otvos","year":"1991","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib16","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1161\/ATVBAHA.120.315639","article-title":"Per-particle triglyceride-rich lipoproteins imply higher myocardial infarction risk than low-density lipoproteins: copenhagen general population study","volume":"41","author":"Johansen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100148","article-title":"LDL-C calculated by friedewald, martin-hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials","volume":"63","author":"Ginsberg","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia And\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib20","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28817","article-title":"Comparison of methods to estimate low-density lipoprotein cholesterol in patients with high triglyceride levels","volume":"4","author":"Sajja","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cll.2006.07.004","article-title":"Cholesterol profile measurement by vertical auto profile method","volume":"26","author":"Kulkarni","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","article-title":"Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants","volume":"12","author":"Nordestgaard","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"Boren","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib28","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib29","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK biobank study","volume":"44","author":"Bjornson","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2023.03.012","article-title":"Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: a systemic review and meta-analysis","volume":"371","author":"Yang","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib32","article-title":"An epidemiological cohort study with repeated measurements: history, course, and results","author":"Jensen","year":"2025","journal-title":"Scand J Publ Health"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib33","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality","volume":"44","author":"Wadstrom","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib34","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jacc.2024.12.033","article-title":"Elevated remnant and LDL cholesterol and the risk of peripheral artery disease: a mendelian randomization study","volume":"85","author":"Wadstrom","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib36","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2025.09.015","article-title":"Remnant cholesterol as an independent cardiovascular risk factor in young adults: an age-stratified cohort study","volume":"86","author":"Jung","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib37","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2025.08.097","article-title":"Remnant cholesterol and cardiovascular risk in young adults: moving beyond low-density lipoprotein cholesterol","volume":"86","author":"Rosenson","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.045376","article-title":"Remnant cholesterol and atherosclerotic cardiovascular disease risk in populations with different low-density lipoprotein cholesterol elevations: a prospective cohort study","volume":"15","author":"Zheng","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib39","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacl.2025.09.008","article-title":"Remnant cholesterol and associations with incidence, progression, and change in coronary artery calcium in South Asian Americans","volume":"19","author":"Manghis","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024366","article-title":"Remnant cholesterol predicts risk of cardiovascular events in patients with myocardial infarction with nonobstructive coronary arteries","volume":"11","author":"Gao","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf683","article-title":"Impact of remnant cholesterol on cardiovascular outcomes in non-myocardial infarction patients undergoing percutaneous coronary intervention","author":"Pitaro","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib42","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib43","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","article-title":"Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial","volume":"31","author":"Zimerman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","article-title":"Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia","volume":"275","author":"Bakker-Arkema","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00019501-200403000-00008","article-title":"Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia","volume":"15","author":"Hunninghake","year":"2004","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib48","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib49","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurjpc\/zwaf203","article-title":"Remnant cholesterol reduction for atherosclerotic cardiovascular disease prevention: modelling in the copenhagen general population study","volume":"32","author":"Hvid","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib51","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib54","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2025.03.496","article-title":"Effect of targeting ApoC-III with plozasiran on lipoprotein particle size and number in hypertriglyceridemia","volume":"85","author":"Ballantyne","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.126.080012","article-title":"Effect of APOC3 inhibition with olezarsen on coronary atherosclerosis: essence-TIMI 73b imaging study","author":"Marston","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2420721122","article-title":"ANGPTL3\/8 is an atypical unfoldase that regulates intravascular lipolysis by catalyzing unfolding of lipoprotein lipase","volume":"122","author":"Kumari","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/CIRCULATIONAHA.124.069272","article-title":"Associations of circulating ANGPTL3, C-Terminal domain-containing ANGPTL4, and ANGPTL3\/8 and ANGPTL4\/8 complexes with LPL activity, diabetes, inflammation, and cardiovascular mortality","volume":"151","author":"Silbernagel","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib60","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2025.07.005","article-title":"Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: a phase 2b trial","volume":"19","author":"Rosenson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib61","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10557-024-07567-z","article-title":"Evinacumab reduces triglyceride-rich lipoproteins in patients with hyperlipidemia: a post-hoc analysis of three randomized clinical trials","volume":"39","author":"Rosenson","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib63","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib64","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib65","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib66","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib67","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120755_bib68","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:23:11Z","timestamp":1781554991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026001218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":68,"alternative-id":["S0021915026001218"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120755","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remnant cholesterol \u2014 The transition from biomarker to risk factor","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120755"}}